What is the Akebia Therapeutics Inc. stock price forecast?

Akebia Therapeutics Inc. is currently trading at $1.50. View real-time AI analysis on Alpha Lenz.

What is Akebia Therapeutics Inc. insider trading activity?

View the latest insider trading data for Akebia Therapeutics Inc. on Alpha Lenz.

What is Akebia Therapeutics Inc.'s P/E ratio?

Akebia Therapeutics Inc.'s P/E ratio is -4.4.

Akebia Therapeutics Inc.

NASDAQ · AKBA

$1.50+0.04(+3.10%)

Ask about Akebia Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Akebia Therapeutics Inc. trades at a P/E of -4.4 (undervalued) with strong ROE of 174.0%.”

Ask for details →

Company Overview

Akebia Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for patients with kidney disease. It leverages its expertise in kidney disease biology to advance its pipeline of innovative therapies aimed at treating conditions such as chronic kidney disease (CKD). The company's lead product, vadadustat, is designed to simulate the body's response to reduced oxygen levels, providing an oral treatment for anemia due to CKD. Akebia's operations encompass both the development and partnership aspects, collaborating with academic institutions and pharmaceutical companies to maximize the impact of its therapies. Headquartered in Cambridge, Massachusetts, Akebia plays a significant role in the healthcare sector by addressing unmet medical needs in nephrology. The company's commitment to improving patient lives through scientific innovation positions it as a significant player in the biopharmaceutical landscape.

CEOMr. John P. Butler MBA

Websitehttps://www.akebia.com

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees181

Company Statistics

FY 2024

Profile

$305.87MMarket Cap

$160.18MRevenue

0.00Shares Out

181Employees

Margins

60.56%Gross

-8.00%EBITDA

-31.47%Operating

-43.33%Pre-Tax

-43.33%Net

Valuation

-4.41P/E

-6.22P/B

1.91EV/Sales

-23.54EV/EBITDA

-7.52P/FCF

Growth (CAGR)

-8.87%Rev 3Yr

-13.72%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-30.02%ROA

174.03%ROE

-22.16%ROIC

Financial Health

$51.87MCash & Cash Equivalents

$217.99MNet Debt

-548.65%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Akebia Therapeutics Inc. trades at a P/E of -4.4 (undervalued) with strong ROE of 174.0%.”

Ask for details →

Frequently Asked Questions

Akebia Therapeutics Inc. (ticker: AKBA) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 181 employees. Market cap is $306M.

The current price is $1.495 with a P/E ratio of -4.41x and P/B of -6.22x.

ROE is 174.03% and operating margin is -31.47%. Annual revenue is $160M.